Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma

NCT07239622 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Ovarian Clear Cell Carcinoma

Interventions

DRUG: Treatment

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University